Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of intravitreal ziv-aflibercept in retinal diseases in Ghana
PACTR201701001940111Not yet recruiting
- Sponsor
- Imoro Zeba braimah
- Start
- Feb 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of aflibercept in diabetic macular edema (DME), Vein occlusion (RVO) and exudative macular degeneration, sponsored by Imoro Zeba braimah. Primary endpoint: Safety of intravitreal ziv-aflibercept. Planned start Feb 2017; status: not yet recruiting.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)Vein occlusion (RVO)exudative macular degeneration
Beyond the preview
Go deeper on PACTR201701001940111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201701001940111.